Research Topics
Genomes and GenesSpecies | Alex A AdjeiSummaryAffiliation: Roswell Park Cancer Institute Country: USA Publications
| Collaborators
|
Detail Information
Publications
Correlation between polymorphisms of the reduced folate carrier gene (SLC19A1) and survival after pemetrexed-based therapy in non-small cell lung cancer: a North Central Cancer Treatment Group-based exploratory studyAraba A Adjei
Departments of Pharmacology and Therapeutics, Roswell Park Cancer Institute, Buffalo, NY 14263, USA
J Thorac Oncol 5:1346-53. 2010..To correlate polymorphisms in genes involved in the transport, activation, and inactivation of pemetrexed with the outcome of patients with advanced non-small cell lung cancer (NSCLC) treated with pemetrexed...- Long-term safety and tolerability of sorafenib in patients with advanced non-small-cell lung cancer: a case-based reviewAlex A Adjei
Roswell Park Cancer Institute, Buffalo, NY 14263, USA
Clin Lung Cancer 12:212-7. 2011..Currently, minimal data are available describing the long-term safety and tolerability of sorafenib in patients with NSCLC... 
Phase I trial of sorafenib in combination with gefitinib in patients with refractory or recurrent non-small cell lung cancerAlex A Adjei
Roswell Park Cancer Institute, Buffalo, New York 14263, USA
Clin Cancer Res 13:2684-91. 2007..To evaluate the combination of sorafenib and gefitinib in patients with advanced non-small cell lung cancer...
Phase II trial of pemetrexed plus bevacizumab for second-line therapy of patients with advanced non-small-cell lung cancer: NCCTG and SWOG study N0426Alex A Adjei
Roswell Park Cancer Institute, Buffalo, NY 14263, USA
J Clin Oncol 28:614-9. 2010....- Early clinical development of ARQ 197, a selective, non-ATP-competitive inhibitor targeting MET tyrosine kinase for the treatment of advanced cancersAlex A Adjei
Roswell Park Cancer Institute, Buffalo, New York, USA
Oncologist 16:788-99. 2011.... - Novel designs and end points for phase II clinical trialsAlex A Adjei
Roswell Park Cancer Institute, Buffalo, New York, USA
Clin Cancer Res 15:1866-72. 2009..Third, rational incorporation of biomarkers into phase II trials should be encouraged. Last, novel imaging modalities will be critical in evaluating the clinical benefit of new cytostatic agents... - Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancersAlex A Adjei
Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA
J Clin Oncol 26:2139-46. 2008..To assess the tolerability, pharmacokinetics (PKs), and pharmacodynamics (PDs) of the mitogen-activated protein kinase kinase (MEK) 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancer... - K-ras as a target for lung cancer therapyAlex A Adjei
Department of Medicine, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA
J Thorac Oncol 3:S160-3. 2008..However, many of these agents have multiple targets, and their antitumor effects may not be due to K-ras inhibition. To date, no selective, specific inhibitor of the K-ras pathway is available for routine clinical use... - Novel small-molecule inhibitors of the vascular endothelial growth factor receptorAlex A Adjei
Roswell Park Cancer Institute, Buffalo, NY 14263, USA
Clin Lung Cancer 8:S74-8. 2007..There are several small-molecule inhibitors of tyrosine kinase activity of VEGF receptors in clinical trials. These are discussed in this review... - Cancer symposium for the practitioner: introduction to solid tumorsAlex A Adjei
Department of Medicine, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA
Mayo Clin Proc 82:107-9. 2007 - Phase I study of Rigosertib, an inhibitor of the phosphatidylinositol 3-kinase and Polo-like kinase 1 pathways, combined with gemcitabine in patients with solid tumors and pancreatic cancerWen Wee Ma
Roswell Park Cancer Institute, Buffalo, New York University of Colorado Cancer Center, Aurora, CO 80045, USA
Clin Cancer Res 18:2048-55. 2012..This phase I study aimed to determine the recommended phase II dose (RPTD) of the combination of rigosertib and gemcitabine in patients with cancer... - A front-line window of opportunity phase 2 study of sorafenib in patients with advanced nonsmall cell lung cancer: North Central Cancer Treatment Group Study N0326Grace K Dy
Department of Medicine, Roswell Park Cancer Institute, Buffalo, New York 14263, USA
Cancer 116:5686-93. 2010..The current study was conducted to assess the efficacy and toxicity of sorafenib as front-line therapy in patients with stage IIIB (pleural effusion) or IV nonsmall cell lung cancer (NSCLC)... - A phase IB study of the pharmacokinetics of gemcitabine and pemetrexed, when administered in rapid sequence to patients with advanced solid tumorsGrace K Dy
Department of Medicine, Mayo Clinic and Foundation, 200 First Street SW, Rochester, MN 55905, USA
Cancer Chemother Pharmacol 55:522-30. 2005..Eight patients had disease stabilization for five or more cycles. CONCLUSION: Gemcitabine immediately followed by pemetrexed is well tolerated and clinically active, and deserves further evaluation in phase II trials... - Brief report: a phase II "window-of-opportunity" frontline study of the MTOR inhibitor, temsirolimus given as a single agent in patients with advanced NSCLC, an NCCTG studyThanyanan Reungwetwattana
Mayo Clinic Cancer Center, Rochester MN, USA
J Thorac Oncol 7:919-22. 2012..In an effort to evaluate the single agent activity of temsirolimus in previously untreated non-small-cell lung cancer, the North Central Cancer Treatment Group undertook a frontline "window-of-opportunity" study... - Improved response to nab-paclitaxel compared with cremophor-solubilized paclitaxel is independent of secreted protein acidic and rich in cysteine expression in non-small cell lung cancerHuanjie Shao
Department of Medicine, Roswell Park Cancer Institute, Buffalo, New York, USA
J Thorac Oncol 6:998-1005. 2011..We aim to demonstrate the role of SPARC expression as biomarker for treatment selection using ABX in NSCLC and to evaluate the presence of synergistic antitumor effect when a demethylating agent is combined with ABX... - Angiogenesis inhibitors in lung cancer: a promise fulfilledGrace K Dy
Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA
Clin Lung Cancer 7:S145-9. 2006..In this review, we will discuss various aspects of this pivotal trial and highlight issues relevant to angiogenesis inhibition in the treatment of non-small-cell lung cancer... - Farnesyltransferase inhibitors in breast cancer therapyGrace K Dy
Department of Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
Cancer Invest 20:30-7. 2002..Thus, the role of other protein targets in mediating the antitumor effect of FTIs is being elucidated. This article reviews current data on the use of FTIs in breast cancer... - Novel agents on the horizon for cancer therapyWen W Ma
Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY, USA
CA Cancer J Clin 59:111-37. 2009..This review also highlights the pipeline of rationally designed drugs in clinical development that have the potential to impact clinical care in the near future... - Phase I and pharmacological study of cytarabine and tanespimycin in relapsed and refractory acute leukemiaScott H Kaufmann
Division of Hematology, Department of Medicine, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
Haematologica 96:1619-26. 2011..We report here the results of a phase I and pharmacological study of the cytarabine + tanespimycin combination in adults with recurrent or refractory acute leukemia... - Dual targeting of mTORC1/C2 complexes enhances histone deacetylase inhibitor-mediated anti-tumor efficacy in primary HCC cancer in vitro and in vivoHuanjie Shao
Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY 14263, USA
J Hepatol 56:176-83. 2012..Therefore, dual targeting of mTORC1/C2 should be more efficient in suppressing AKT activity and in enhancing the anti-tumor activity of HDACi in HCC... - Comparison of continuous versus categorical tumor measurement-based metrics to predict overall survival in cancer treatment trialsMing Wen An
Department of Mathematics, Vassar College, Poughkeepsie, New York, USA
Clin Cancer Res 17:6592-9. 2011..The categorical definition of response assessed via the Response Evaluation Criteria in Solid Tumors has documented limitations. We sought to identify alternative metrics for tumor response that improve prediction of overall survival... - Emerging therapeutic targets in non-small cell lung cancerGrace K Dy
Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY 14263, USA
Proc Am Thorac Soc 6:218-23. 2009..This review highlights the biological targets relevant in the treatment of non-small cell lung cancer... - Complementary and alternative medicine use by patients enrolled onto phase I clinical trialsGrace K Dy
Division of Medical Oncology, Department of Medicine, Mayo Foundation and Mayo Clinic College of Medicine, Rochester, MN, USA
J Clin Oncol 22:4810-5. 2004..CONCLUSION: CAM use is common among patients in phase I trials and should be ascertained by investigators, because some of the agents used may interact with investigational agents and affect adverse effects and/or efficacy... - Analysis of second primary lung cancers in the SEER databaseAmrit Bhaskarla
Department of Thoracic Surgery, Roswell Park Cancer Institute, Buffalo, New York 14263, USA
J Surg Res 162:1-6. 2010..We also sought to study the outcomes of synchronous second non-small-cell lung cancers (NSCLCs), classified as stage IVA (M1A) according to the seventh edition of the TNM staging for lung cancer... - A randomized phase II study of gemcitabine and carboplatin with or without cediranib as first-line therapy in advanced non-small-cell lung cancer: North Central Cancer Treatment Group Study N0528Grace K Dy
Department of Medicine, Roswell Park Cancer Institute, Buffalo, New York, USA
J Thorac Oncol 8:79-88. 2013..The purpose of this study was to assess the safety and efficacy of gemcitabine and carboplatin with (arm A) or without (arm B) daily oral cediranib as first-line therapy for advanced non-small-cell lung cancer... - Small cell lung cancerTaimur Sher
Department of Medicine, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA
Mayo Clin Proc 83:355-67. 2008..Other novel agents such as bevacizumab have shown promising early results and are being evaluated in larger trials... - Mitochondrial Bax translocation partially mediates synergistic cytotoxicity between histone deacetylase inhibitors and proteasome inhibitors in glioma cellsChunrong Yu
Department of Medicine, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA
Neuro Oncol 10:309-19. 2008..This combination regimen warrants further preclinical and possible clinical study for glioma patients... - Novel targets for lung cancer therapy: part IIGrace K Dy
Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA
J Clin Oncol 20:3016-28. 2002..Future approaches to treatment are suggested... - Systemic cancer therapy: evolution over the last 60 yearsGrace K Dy
Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY 14263, USA
Cancer 113:1857-87. 2008..The key approaches and evidence pertinent to the clinical development of these novel agents are presented in this review... - Thoracoscopic organ suffusion for regional lung chemotherapy (preliminary results)Todd L Demmy
Department of Thoracic Surgery, Roswell Park Cancer Institute, Buffalo, New York 14263, USA
Ann Thorac Surg 88:385-90; discussion 390-1. 2009..After promising preclinical studies using a thoracoscopic regional lung chemotherapy technique less morbid than open perfusion methods, we initiated a Phase I clinical study... - Targeting multiple signal transduction pathways in lung cancerAlex A Adjei
Division of Medical Oncology, Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA
Clin Lung Cancer 7:S39-44. 2005..These inhibitors include ZD6474, SU11248, AEE 788, sorafenib, vatalanib, and AG-013736... - Novel targets for lung cancer therapy: part IGrace K Dy
Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA
J Clin Oncol 20:2881-94. 2002..In this article, agents inhibiting growth factor receptors and various molecules downstream of activated signaling cascades, such as cytoplasmic second messengers, are described... - Phase I and pharmacologic study of infusional topotecan and Carboplatin in relapsed and refractory acute leukemiaScott H Kaufmann
Division of Hematology, Department of Medicine, Mayo Clinic College of Medicine, Rochester, MN 55901, USA
Clin Cancer Res 11:6641-9. 2005..To assess the maximum tolerated dose, toxicities, pharmacokinetics, and antileukemic activity of topotecan and carboplatin in adults with recurrent or refractory acute leukemias... - The Akt/mTOR and mitogen-activated protein kinase pathways in lung cancer therapyVassiliki Papadimitrakopoulou
MD Anderson Cancer Center, Houston, Texas 77030, USA
J Thorac Oncol 1:749-51. 2006..We review current information on the therapeutic manipulation of these targets and describe early clinical data in lung cancer... - Impact of pretreatment factors on adverse events: a pooled analysis of North Central Cancer Treatment Group advanced stage non-small cell lung cancer trialsSumithra J Mandrekar
Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
J Thorac Oncol 1:556-63. 2006..This pooled analysis was performed to examine the impact of pretreatment factors on severe (grade 3 or higher) adverse events (AE) in patients with advanced stage non-small cell lung cancer (NSCLC)... - Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorshipJulian R Molina
Department of Oncology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
Mayo Clin Proc 83:584-94. 2008.... - A phase I trial of twice-weekly 17-allylamino-demethoxy-geldanamycin in patients with advanced cancerGrzegorz S Nowakowski
Department of Oncology, Cancer Center Statistics, Mayo Clinic, Rochester, Minnesota 55905, USA
Clin Cancer Res 12:6087-93. 2006..This raises the possibility that HSP70 induction as part of the stress response may contribute to resistance to 17-AAG... - Cooperative group portfolio in locally advanced non-small-cell lung cancer: are we making progress?Corey J Langer
Thoracic Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
Clin Lung Cancer 9:85-91. 2008..These efforts focus on radiation dose escalation using image-guided radiation therapy as well as newer cytotoxic agents (eg, pemetrexed) and targeted therapies (eg, cetuximab, bevacizumab, and etc) thus far unexplored in this setting... - A Phase I trial of the farnesyl protein transferase inhibitor R115777 in combination with gemcitabine and cisplatin in patients with advanced cancerAlex A Adjei
Mayo Clinic and Foundation, Departments of Oncology and Medicine, Rochester, Minnesota 55905, USA
Clin Cancer Res 9:2520-6. 2003..This Phase I study was undertaken to define the toxicity, pharmacodynamics, and maximum tolerated dose of the combination of R115777, a farnesyl transferase inhibitor, with gemcitabine and cisplatin in patients with advanced solid tumors... - The value of combined-modality therapy in elderly patients with stage III nonsmall cell lung cancerSteven E Schild
Department of Radiation Oncology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota, USA
Cancer 110:363-8. 2007.... - Mcl-1 as a buffer for proapoptotic Bcl-2 family members during TRAIL-induced apoptosis: a mechanistic basis for sorafenib (Bay 43-9006)-induced TRAIL sensitizationXue Wei Meng
Divisions of Oncology Research, Department of Oncology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
J Biol Chem 282:29831-46. 2007..Collectively, these observations not only suggest a model in which Mcl-1 confers TRAIL resistance by serving as a buffer for Bak, Bim, and Puma, but also identify sorafenib as a potential modulator of TRAIL sensitivity... - Phase I dose escalation study of the anti insulin-like growth factor-I receptor monoclonal antibody CP-751,871 in patients with refractory solid tumorsPaul Haluska
Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
Clin Cancer Res 13:5834-40. 2007..This phase I study was undertaken to define the maximum tolerated dose, safety, and pharmacokinetic profile of CP-751,871... - Phase III randomized, double-blind study of maintenance CAI or placebo in patients with advanced non-small cell lung cancer (NSCLC) after completion of initial therapy (NCCTG 97-24-51)Elizabeth A Johnson
Mayo Clinic Jacksonville, Jacksonville, FL 32224, USA
Lung Cancer 60:200-7. 2008.... - Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapyBret B Friday
Department of Oncology, Mayo Clinic, Rochester, MN, USA
Clin Cancer Res 14:342-6. 2008..Herein, we review the MAPK pathway, the development of small-molecule MEK inhibitors, and the results obtained to date with MEK inhibitors in human cancer trials... - BRAF V600E disrupts AZD6244-induced abrogation of negative feedback pathways between extracellular signal-regulated kinase and Raf proteinsBret B Friday
Department of Oncology, Mayo Clinic, Rochester, Minnesota, USA
Cancer Res 68:6145-53. 2008..These data suggest an approach to identifying cells that may be sensitive to AZD6244 and other MEK inhibitors... - Advances in chemotherapy of non-small cell lung cancerJulian R Molina
Division of Medical Oncology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
Chest 130:1211-9. 2006.... - Cytotoxic synergy between the multikinase inhibitor sorafenib and the proteasome inhibitor bortezomib in vitro: induction of apoptosis through Akt and c-Jun NH2-terminal kinase pathwaysChunrong Yu
Department of Oncology, Mayo Clinic, Rochester, MN 55905, USA
Mol Cancer Ther 5:2378-87. 2006..Further clinical development of this combination seems warranted... - What is the right dose? The elusive optimal biologic dose in phase I clinical trialsAlex A Adjei
J Clin Oncol 24:4054-5. 2006 - A phase I trial of the novel farnesyl protein transferase inhibitor, BMS-214662, in combination with paclitaxel and carboplatin in patients with advanced cancerGrace K Dy
Department of Oncology, Mayo Clinic and Foundation, 200 First Street SW, Rochester, MN 55905, USA
Clin Cancer Res 11:1877-83. 2005..There was no correlation between dose level and accumulation of unfarnesylated HDJ-2 in PBMCs nor tumor response... - Comparative pharmacokinetic study of continuous venous infusion fluorouracil and oral fluorouracil with eniluracil in patients with advanced solid tumorsAlex A Adjei
Mayo Clinic and Foundation, Department of Oncology, Rochester, MN 55905, USA
J Clin Oncol 20:1683-91. 2002..To compare the pharmacokinetics of continuous venous infusion (CVI) fluorouracil (5-FU) with that of oral eniluracil/5-FU and to describe toxicities and clinical activity of prolonged oral administration of eniluracil/5-FU... - Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancerJohn Rinehart
University of Alabama at Birmingham, Birmingham, AL 35294, USA
J Clin Oncol 22:4456-62. 2004.... - Pemetrexed (ALIMTA), a novel multitargeted antineoplastic agentAlex A Adjei
Mayo Clinic and Foundation, Departments of Oncology, Rochester, Minnesota, USA
Clin Cancer Res 10:4276s-4280s. 2004..Low level dietary supplement of folic acid and vitamin B12 has significantly decreased the mucosal and bone marrow toxicity of pemetrexed without compromising its antitumor effect... - Novel agents in the treatment of lung cancer: conference summary statementThomas J Lynch
Division of Hematology/Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA
Clin Cancer Res 10:4199s-4204s. 2004 - Farnesyltransferase inhibitorsSaid M Sebti
H. Lee Moffitt Cancer Center, Tampa, FL, USA
Semin Oncol 31:28-39. 2004..Activity has been shown in hematologic malignancies (acute myeloid leukemia, chronic myeloid leukemia, myelodysplastic syndrome), breast cancer, and glioma. Several combination studies of FTIs and standard cytotoxic agents are ongoing... - Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myelomaMelissa Alsina
Experimental Therapeutics Program, H. Lee Moffitt Cancer Center and Research Institute and Department of Oncology, University of South Florida, Tampa, FL 33612, USA
Blood 103:3271-7. 2004..We conclude that tipifarnib is tolerable, can induce disease stabilization, and can inhibit farnesylation and oncogenic/tumor survival pathways... - The role of Pemetrexed (Alimta , LY231514) in lung cancer therapyJulian R Molina
Division of Medical Oncology, Mayo Clinic, Rochester, MN, USA
Clin Lung Cancer 5:21-7. 2003..In this review, the pharmacology and clinical activity of pemetrexed in NSCLC cancer is discussed... - Novel anticancer agents in clinical developmentAlex A Adjei
Mayo Clinic and Foundation Rochester, Minnesota 55905, USA
Cancer Biol Ther 2:S5-15. 2003..This review will highlight promising rationally designed, target-based agents in clinical development, as well as the unique challenges involved in their successful development... - Phase I and pharmacokinetic study of two different schedules of oxaliplatin, irinotecan, Fluorouracil, and leucovorin in patients with solid tumorsMatthew P Goetz
Department of Neurology, Mayo Clinic, Rochester, MN 55905, USA
J Clin Oncol 21:3761-9. 2003..Additionally, we investigated the effect of CPT-11 on oxaliplatin pharmacokinetics... - An overview of farnesyltransferase inhibitors and their role in lung cancer therapyAlex A Adjei
Department of Oncology, Mayo Clinic, 200 First Street S W, Rochester, MN 55905, USA
Lung Cancer 41:S55-62. 2003..However, current evidence suggests that the antitumor activity of FTIs may be ras-independent. This article reviews preclinical and clinical data pertinent to the use of FTIs in lung cancer... - A phase I and pharmacologic study of pyrazoloacridine and cisplatin in patients with advanced cancerE Claire Dees
Division of Hematology and Oncology, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
Invest New Drugs 21:75-84. 2003..Pharmacokinetic analysis showed that sequence does not impact on the pharmacokinetics of PZA when given in combination with cisplatin... - Phase II study of the farnesyl transferase inhibitor R115777 in patients with advanced non-small-cell lung cancerAlex A Adjei
Department of Onclogy, Division of Medical Oncology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
J Clin Oncol 21:1760-6. 2003..This phase II study was undertaken to define the efficacy and pharmacodynamics of R115777, a farnesyl transferase inhibitor, in the first-line treatment of patients with advanced non-small-cell lung cancer... - Preclinical and clinical studies with combinations of pemetrexed and gemcitabineAlex A Adjei
Division of Medical Oncology, Mayo Clinic, Rochester, MN 55905, USA
Semin Oncol 29:30-4. 2002..Phase II studies of this combination are being performed in breast and non-small cell lung cancer. In addition, a phase III study in pancreatic cancer is ongoing... - A phase I trial of ISIS 2503, an antisense inhibitor of H-ras, in combination with gemcitabine in patients with advanced cancerAlex A Adjei
Department of Oncology, Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA
Clin Cancer Res 9:115-23. 2003..The purpose of this study was to define the toxicity, pharmacokinetics, and clinical activity of the combination of ISIS 2503, an oligodeoxynucleotide antisense inhibitor of H-ras, and gemcitabine in patients with advanced solid tumors... - Inhibitors of the ras oncogene as therapeutic targetsIrene M Ghobrial
Division of Medical Oncology, Mayo Clinic, 200 First Street Southwest, Rochester, MN 55905, USA
Hematol Oncol Clin North Am 16:1065-88. 2002.... - Results of combined-modality therapy for limited-stage small cell lung carcinoma in the elderlySteven E Schild
Department of Radiation Oncology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota, USA
Cancer 103:2349-54. 2005..No difference in survival was identified between the two arms. The current analysis examined the relation between age and outcome for patients treated during this trial... - A phase I and pharmacologic trial of two schedules of the proteasome inhibitor, PS-341 (bortezomib, velcade), in patients with advanced cancerGrace K Dy
Mayo Clinic, Rochester, Minnesota, 55905, USA
Clin Cancer Res 11:3410-6. 2005..A patient with multiple myeloma had a partial response. CONCLUSION: PS-341 given 1.5 mg/m2 twice weekly for 2 of every 3 weeks is well tolerated and should be further studied... - A phase II study of bortezomib in the treatment of metastatic malignant melanomaSvetomir N Markovic
Melanoma Study Group, Mayo Clinic and Mayo Foundation, Rochester, Minnesota, USA
Cancer 103:2584-9. 2005..Bortezomib is a proteasome inhibitor with manageable clinical toxicity and laboratory evidence of anti-melanoma activity. Therefore, it was considered for clinical testing in patients with metastatic melanoma... - Novel combinations based on epidermal growth factor receptor inhibitionAlex A Adjei
Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota 55905, USA
Clin Cancer Res 12:4446s-4450s. 2006..A brief overview of some of these pathways (mammalian target of rapamycin, vascular endothelial growth factor receptor, and ras/mitogen-activated protein kinase signaling) is provided in this review... - Summary statement: novel agents in the treatment of lung cancer: advances in epidermal growth factor receptor-targeted agentsThomas J Lynch
Division of Hematology/Oncology, Massachusetts General Hospital, Boston 02114, and University of Colorado Cancer Center, Aurora, USA
Clin Cancer Res 12:4365s-4371s. 2006 - A prognostic model for advanced stage nonsmall cell lung cancer. Pooled analysis of North Central Cancer Treatment Group trialsSumithra J Mandrekar
Mayo Clinic College of Medicine, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
Cancer 107:781-92. 2006.... - A Phase II NCCTG study of irinotecan and docetaxel in previously treated patients with non-small cell lung cancerJulian R Molina
Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
Cancer Invest 24:382-9. 2006..6 months and 7.5 months, respectively. CONCLUSION: This second-line treatment regimen of irinotecan and docetaxel in NSCLC patients has shown activity, but can not be recommended over single-agent regimens because of significant toxicity... - Inhibitors of growth factor receptors, signaling pathways and angiogenesis as therapeutic molecular agentsJocelyn Holash
Regeneron Pharmaceuticals, Tarrytown, NY, USA
Cancer Metastasis Rev 25:243-52. 2006 - Phase I study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor, in patients with advanced solid tumorsCharles Erlichman
Department of Oncology, Mayo Clinic, Rochester, MN 55902, USA
J Clin Oncol 24:2252-60. 2006.... - The role of mitogen-activated ERK-kinase inhibitors in lung cancer therapyAlex A Adjei
Division of Medical Oncology, Mayo Clinic and Foundation, Rochester, MN 55905, USA
Clin Lung Cancer 7:221-3. 2005..The most promising approach to date appears to be the inhibition of mitogen-activated ERK kinase or MEK. In this review, the potential utility of MEK inhibitors in the therapy of lung cancer is discussed... - Obstacles and opportunities in the clinical development of targeted therapeuticsGrace K Dy
Department of Internal Medicine, Mayo Clinic College of Medicine, 200 First St. SW, Rochester, MN 55905, USA
Prog Drug Res 63:19-41. 2005 - Sequencing bortezomib with chemotherapy and targeted agentsAlex A Adjei
Department of Oncology, Mayo Clinic, Rochester, MN 55905, USA
Clin Lung Cancer 7:S56-8. 2005..This review provides an overview of selected interactions between bortezomib and other anticancer agents preclinically and in early clinical trials... - K-ras as a target for cancer therapyBret B Friday
Division of Medical Oncology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
Biochim Biophys Acta 1756:127-44. 2005.... - Randomized phase II trial of three schedules of pemetrexed and gemcitabine as front-line therapy for advanced non-small-cell lung cancerCynthia X Ma
Department of Oncology and Medicine, Mayo Clinic and Foundation, 200 First St SW, Rochester, MN 55905, USA
J Clin Oncol 23:5929-37. 2005..CONCLUSION: Pemetrexed and gemcitabine administered as outlined for schedule A met the protocol-defined efficacy criteria, was less toxic compared with the other treatment schedules, and should be further evaluated... - Phase 1 trial of flavopiridol combined with cisplatin or carboplatin in patients with advanced malignancies with the assessment of pharmacokinetic and pharmacodynamic end pointsKeith C Bible
Division of Medical Oncology, Mayo Clinic, Rochester, Minnesotta 55905, USA
Clin Cancer Res 11:5935-41. 2005.... - Ramifications of severe organ dysfunction in newly diagnosed patients with small cell lung cancer: contemporary experience from a single institutionKarin F Giordano
Division of Medical Oncology, Mayo Clinic, Rochester, MN 55905, USA
Lung Cancer 49:209-15. 2005.... - Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignanciesPatricia M LoRusso
Barbara Ann Karmanos Cancer Institute, 4100 John R 4 HWCRC, Room 4206, Detroit, MI 48201, USA
J Clin Oncol 23:5281-93. 2005.... - The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006Chunrong Yu
Division of Medical Oncology, Mayo Clinic, 200 First Street. SW, Rochester, MN 55905, USA
Oncogene 24:6861-9. 2005..Conversely, Mcl-1 downregulation by short hairpin RNA enhanced BAY 43-9006-induced apoptosis. Collectively, these findings demonstrate that drug-induced Mcl-1 downregulation contributes to the proapoptotic effects of BAY 43-9006... - Targeting apoptosis pathways in cancer therapyIrene M Ghobrial
Division of Hematology, Department of Internal Medicine, University of Pittsburgh, PA, USA
CA Cancer J Clin 55:178-94. 2005..This article reviews the current understanding of the apoptotic pathways, including the extrinsic (cytoplasmic) and intrinsic (mitochondrial) pathways, and the agents being developed to target these pathways... - A phase I and pharmacologic study of pyrazoloacridine (NSC 366140) and carboplatin in patients with advanced cancerAlex A Adjei
Division of Medical Oncology, Mayo Clinic, Mayo Graduate School, Rochester, MN 55905, USA
Invest New Drugs 20:297-304. 2002..Subsequent studies revealed that PZA inhibits removal of platinum-DNA adducts in cultured A549 cells. Based on these results, we undertook a phase I study of the combination of PZA and carboplatin (CBDCA)...